An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the ILDR2 Function-blocking Antibody BAY1905254 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Nov 2019
Price : $35 *
At a glance
- Drugs BAY 1905254 (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Bayer
- 25 Nov 2019 Planned number of patients changed from 198 to 236.
- 19 Sep 2019 Planned number of patients changed from 196 to 198.
- 10 Jan 2019 Planned End Date changed from 30 Nov 2021 to 14 Jul 2023.